Fig 1.
Effect of endocrine therapy on the growth of ZR-75-1 xenografts.
** P< 0.001 compared to the vehicle group.
Fig 2.
18F-FES PET/CT imaging of ZR-75-1 tumor-bearing mice.
(A) Representative ZR-75-1 tumors were imaged using PET/CT with 18F-FES on days 0, 3, 14, and 21 after treatment. The tumors are indicated by arrows. (B, C) 18F-FES PET/CT analysis (%ID/gmax and T/M) on days 0, 3, 14, and 21 after treatment. ** P< 0.001, within groups compared to baseline; # P< 0.05, ## P< 0.001 between treatment and vehicle groups.
Fig 3.
18F-FDG PET/CT imaging of ZR-75-1 tumor-bearing mice.
(A) Representative ZR-75-1 tumors were imaged using PET/CT with 18F-FDG on days 0, 3, 14, and 21 after treatment. The tumors are indicated by arrows. (B, C) 18F-FDG PET/CT analysis (%ID/gmax and T/M) on days 0, 3, 14, and 21 after treatment. * P< 0.05, ** P< 0.001, within groups compared to baseline; # P< 0.05 between treatment and vehicle groups.
Fig 4.
18F-FMISO PET/CT imaging of ZR-75-1 tumor-bearing mice.
(A) Representative ZR-75-1 tumors were imaged using PET/CT with 18F-FMISO on days 0, 3, 14, and 21 after treatment. The tumors are indicated by arrows. (B, C) 18F-FMISO PET/CT analysis (%ID/gmax and T/M) on days 0, 3, 14, and 21 after treatment. * P< 0.05, within groups compared to baseline.
Fig 5.
18F-FES uptake in comparison to IHC results.
There is a significant positive correlation between 18F-FES uptake and ER expression (%ID/gmax, r2 = 0.76, P < 0.05; T/M, r2 = 0.82, P < 0.05).
Fig 6.
Correlation between tumor 18F-FES uptake and tumor growth.
18F-FES Δ%ID/gmax and ΔT/M on day 3, day 14 and day 21 was significantly correlated with the day 21/baseline tumor volume ratio.